Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Motixafortide for Stem Cell Mobilization in Allogeneic Transplant
NCT02639559Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- Mar 2016
- Primary completion
- Apr 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of motixafortide in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), sponsored by Washington University School of Medicine. Started Mar 2016; status: completed.
02
Drugs
motixafortide
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)chronic myeloid leukemia (CML)non-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT02639559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02639559.